Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.

2.50
Hdl Handle:
http://hdl.handle.net/10541/70155
Title:
Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.
Authors:
Meiers, Isabelle; Shanks, Jonathan H; Bostwick, David G
Abstract:
Prostatic carcinoma is characterised by the silencing of the pi-class glutathione S-transferase gene (GSTP1), which encodes a detoxifying enzyme. The silencing of GSTP1 results from aberrant methylation at the CpG island in the promoter-5' and occurs in the vast majority of cases of high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancers. We review the potential novel role of GSTP1 and its related expression in prostate cancer. The loss of expression (silencing) of the GSTP1 gene is the most common (>90%) genetic alteration reported to date in prostate cancer. Quantitative methylation-specific PCR assays allow detection of GSTP1 methylation in prostate biopsies and may improve the sensitivity of cancer detection. Advances in the epigenetic characterisation of prostate cancer have enabled the development of DNA methylation assays that may soon be used in diagnostic testing of serum and tissue for prostate cancer. Inhibition of aberrant promoter methylation could theoretically prevent carcinogenesis.
Affiliation:
Department of Pathology, Bostwick Laboratories, London, United Kingdom. isabellemeiers@hotmail.com
Citation:
Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. 2007, 39 (3):299-304 Pathology
Journal:
Pathology
Issue Date:
Jun-2007
URI:
http://hdl.handle.net/10541/70155
DOI:
10.1080/00313020701329906
PubMed ID:
17558856
Type:
Article
Language:
en
ISSN:
0031-3025
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMeiers, Isabelle-
dc.contributor.authorShanks, Jonathan H-
dc.contributor.authorBostwick, David G-
dc.date.accessioned2009-06-11T10:59:04Z-
dc.date.available2009-06-11T10:59:04Z-
dc.date.issued2007-06-
dc.identifier.citationGlutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. 2007, 39 (3):299-304 Pathologyen
dc.identifier.issn0031-3025-
dc.identifier.pmid17558856-
dc.identifier.doi10.1080/00313020701329906-
dc.identifier.urihttp://hdl.handle.net/10541/70155-
dc.description.abstractProstatic carcinoma is characterised by the silencing of the pi-class glutathione S-transferase gene (GSTP1), which encodes a detoxifying enzyme. The silencing of GSTP1 results from aberrant methylation at the CpG island in the promoter-5' and occurs in the vast majority of cases of high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancers. We review the potential novel role of GSTP1 and its related expression in prostate cancer. The loss of expression (silencing) of the GSTP1 gene is the most common (>90%) genetic alteration reported to date in prostate cancer. Quantitative methylation-specific PCR assays allow detection of GSTP1 methylation in prostate biopsies and may improve the sensitivity of cancer detection. Advances in the epigenetic characterisation of prostate cancer have enabled the development of DNA methylation assays that may soon be used in diagnostic testing of serum and tissue for prostate cancer. Inhibition of aberrant promoter methylation could theoretically prevent carcinogenesis.en
dc.language.isoenen
dc.subjectProstate Canceren
dc.subject.meshDNA Methylation-
dc.subject.meshEpigenesis, Genetic-
dc.subject.meshGlutathione Transferase-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshProstatic Neoplasms-
dc.titleGlutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology, Bostwick Laboratories, London, United Kingdom. isabellemeiers@hotmail.comen
dc.identifier.journalPathologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.